Goldman Sachs’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-939,811
| Closed | -$14.2M | – | 6575 |
|
|
2022
Q3 | $14.2M | Buy |
939,811
+788,150
| +520% | +$9.16M | ﹤0.01% | 2171 |
|
|
2022
Q2 | $1.14M | Sell |
151,661
-121,767
| -45% | -$858K | ﹤0.01% | 4514 |
|
|
2022
Q1 | $2.49M | Buy |
273,428
+46,498
| +20% | +$358K | ﹤0.01% | 4052 |
|
|
2021
Q4 | $1.59M | Buy |
226,930
+12,255
| +6% | +$128K | ﹤0.01% | 4438 |
|
|
2021
Q3 | $2.45M | Sell |
214,675
-18,415
| -8% | -$269K | ﹤0.01% | 3998 |
|
|
2021
Q2 | $3.73M | Buy |
233,090
+13,969
| +6% | +$240K | ﹤0.01% | 3615 |
|
|
2021
Q1 | $3.92M | Sell |
219,121
-37,808
| -15% | -$653K | ﹤0.01% | 3366 |
|
|
2020
Q4 | $3.47M | Sell |
256,929
-932,597
| -78% | -$11.3M | ﹤0.01% | 3295 |
|
|
2020
Q3 | $14M | Buy |
1,189,526
+683,773
| +135% | +$8.33M | ﹤0.01% | 2032 |
|
|
2020
Q2 | $7.46M | Buy |
505,753
+314,691
| +165% | +$4.66M | ﹤0.01% | 2477 |
|
|
2020
Q1 | $2.58M | Buy |
191,062
+99,466
| +109% | +$1.89M | ﹤0.01% | 3125 |
|
|
2019
Q4 | $2.21M | Sell |
91,596
-357,539
| -80% | -$7.41M | ﹤0.01% | 3578 |
|
|
2019
Q3 | $8.63M | Buy |
449,135
+122,082
| +37% | +$2.8M | ﹤0.01% | 2433 |
|
|
2019
Q2 | $9.66M | Buy |
327,053
+158,594
| +94% | +$6.11M | ﹤0.01% | 2380 |
|
|
2019
Q1 | $8M | Buy |
168,459
+73,121
| +77% | +$3.22M | ﹤0.01% | 2603 |
|
|
2018
Q4 | $3.44M | Sell |
95,338
-11,535
| -11% | -$541K | ﹤0.01% | 3178 |
|
|
2018
Q3 | $6.58M | Buy |
106,873
+10,586
| +11% | +$681K | ﹤0.01% | 2775 |
|
|
2018
Q2 | $6.5M | Sell |
96,287
-71,105
| -42% | -$3.98M | ﹤0.01% | 2775 |
|
|
2018
Q1 | $9.08M | Buy |
167,392
+9,415
| +6% | +$527K | ﹤0.01% | 2410 |
|
|
2017
Q4 | $9.44M | Sell |
157,977
-9,252
| -6% | -$561K | ﹤0.01% | 2491 |
|
|
2017
Q3 | $8.13M | Sell |
167,229
-37,600
| -18% | -$2.05M | ﹤0.01% | 2739 |
|
|
2017
Q2 | $10.8M | Sell |
204,829
-18,224
| -8% | -$849K | ﹤0.01% | 2463 |
|
|
2017
Q1 | $10.1M | Buy |
223,053
+49,473
| +29% | +$2.21M | ﹤0.01% | 2404 |
|
|
2016
Q4 | $6.57M | Sell |
173,580
-84,262
| -33% | -$3.19M | ﹤0.01% | 2818 |
|
|
2016
Q3 | $9.73M | Sell |
257,842
-197,400
| -43% | -$4.35M | ﹤0.01% | 2472 |
|
|
2016
Q2 | $8.01M | Buy |
455,242
+34,281
| +8% | +$555K | ﹤0.01% | 2490 |
|
|
2016
Q1 | $5.12M | Buy |
420,961
+398,512
| +1,775% | +$6.31M | ﹤0.01% | 2706 |
|
|
2015
Q4 | $547K | Sell |
22,449
-4,568
| -17% | -$107K | ﹤0.01% | 4838 |
|
|
2015
Q3 | $479K | Sell |
27,017
-257,132
| -90% | -$4.66M | ﹤0.01% | 5180 |
|
|
2015
Q2 | $5.02M | Sell |
284,149
-33,471
| -11% | -$614K | ﹤0.01% | 2959 |
|
|
2015
Q1 | $9.96M | Buy |
317,620
+51,233
| +19% | +$1.48M | ﹤0.01% | 2297 |
|
|
2014
Q4 | $7.78M | Sell |
266,387
-221,942
| -45% | -$5.63M | ﹤0.01% | 2564 |
|
|
2014
Q3 | $10.1M | Buy |
488,329
+178,955
| +58% | +$3.53M | ﹤0.01% | 2357 |
|
|
2014
Q2 | $7.66M | Buy |
+309,374
| New | +$5.36M | ﹤0.01% | 2614 |
|
Goldman Sachs's AERI Position: Q4 2022 in Review
Goldman Sachs sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 939,811 shares — an estimated $14.2M sold.
Goldman Sachs first reported a position in AERI in Q2 2014 and held it in 34 quarters. The position peaked at $14.2M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Goldman Sachs reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Goldman Sachs sold 939,811 Aerie Pharmaceuticals shares in Q4 2022, an estimated $14.2M.
- Goldman Sachs first reported a position in Aerie Pharmaceuticals in Q2 2014 and held it in 34 quarters.
- Goldman Sachs's Aerie Pharmaceuticals position peaked at $14.2M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.